The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial).
 
John Nikitas
No Relationships to Disclose
 
Stephanie Lira
No Relationships to Disclose
 
Zachary Ells
No Relationships to Disclose
 
Shaojun Zhu
Consulting or Advisory Role - SOFIE
 
Tristan Grogan
No Relationships to Disclose
 
David Elashoff
No Relationships to Disclose
 
Adrien Holzgreve
Consulting or Advisory Role - ABX Advanced biochemical compounds
Research Funding - ABX Advanced biochemical compounds (Inst)
 
Lena Unterrainer
No Relationships to Disclose
 
Magnus Dahlbom
No Relationships to Disclose
 
Martin Allen-Auerbach
No Relationships to Disclose
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Aktis Oncology; RayzeBio
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics